Pedro Farinha is an expert in Hematology at BC Cancer Agency (Canada). As of September 2026, ScienceLeadR ranks Pedro Farinha in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Pedro Farinha has authored 223 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 689 (community average: 125). How the SLR is computed.

LeadR Profile

Pedro Farinha BC Cancer Agency Canada
689 ScienceLeadR Reputation 689
Network Map

Hematology

Subspecialties: Oncology - Immunology - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Since the beginning of my pathology training, I have developed a strong interest in hematological malignancies, with a particular focus on integrating routine diagnostic lymphoma practice with translational research. In 2001, I completed a rotation with the BC Cancer Agency’s Lymphoma Tumor Group. After finishing my anatomic pathology residency in Lisbon in 2003, I returned to BC Cancer, where I pursued fellowships in both Molecular Lymphoma Pathology and Clinical Hematopathology. This work culminated in my PhD thesis, “Biological Predictors of Survival in Lymphoma and Mechanisms Underlying Follicular Lymphoma Transformation into Diffuse Large B-Cell Lymphoma.” In 2013, I joined the pathology staff at BC Cancer, where I continue to collaborate with lymphoma research projects through the Centre for Lymphoid Cancer, as well as integrate the UBC Department of Pathology and Laboratory Medicine.

Organizations

Career arc: 2007 - 2026

Source: PubMed

Universidade Nova de Lisboa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 223

Citations

Citations: 13 976 1st author: 26 Last author: 5 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.
PMID 42345068 — cells, cell differentiation, hematology, lymphoma, b-cell, lymphoma, germinal center, lymphoma, large b-cell, diffuse, b-lymphocytes
Haematologica20260
Favourable 16-year outcome of an acetabular reinforcement ring with suboptimal host-bone coverage: the role of biological and mechanical stabilisation.
PMID 42293695 — autografts, developmental dysplasia of the hip, arthroplasty, reinforcement, psychology, osteoarthritis, transplants
J Surg Case Rep20260
Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study.
PMID 42138053 — cells, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, pathologists, diagnosis, b-lymphocytes
Am J Surg Pathol20260
Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.
PMID 41615883 — cells, genes, hodgkin disease, lymphoma, neoplasms, ecosystem, therapeutics, mutation
Cancer Discov20261
Solving the Puzzle of Hans' Algorithm (HA) Methodological Shortcomings: Canadian Harmonization of Hans' Algorithm for Diffuse Large B-Cell Lymphoma (DLBCL) and Development of Fit-for-Purpose Modified Hans' Algorithm (mHA).
PMID 42008333 — cells, gene expression profiling, laboratories, immunohistochemistry, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, algorithms, biomarkers, b-lymphocytes
Appl Immunohistochem Mol Morphol20260

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Terminated 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map